Immunotherapy Is ‘Advance of the Year’ for Second Year – Medscape
Medscape |
Immunotherapy Is 'Advance of the Year' for Second Year
Medscape "In just a few short years, immunotherapy has transformed the outlook" for patients with advanced melanoma, the report notes. "Given the lasting responses seen in a large proportion of patients who have received immunotherapy, experts are beginning to … Report: Trump Administration Should Continue Funding Cancer Research |
